Mounjaro Cost Without Insurance: What You'll Actually Pay in 2026

Quick price guide by situation

How much does Mounjaro cost without insurance in 2026?

Mounjaro cost without insurance is roughly $1,000 to $1,300 for a 28-day supply of four prefilled pens, depending on the pharmacy and your ZIP code. Eli Lilly's wholesale acquisition cost (the official list price) is $1,112.16/month as of the January 2026 update. Per Lilly, the per-fill list price is the same across every dose — but real cash and coupon prices do vary by pharmacy, dose, and coupon vendor, sometimes meaningfully.

What pharmacies typically charge

Cash prices for Mounjaro vary more by pharmacy than by dose. According to current public pricing databases (GoodRx, SingleCare, Drugs.com) and provider pages, the typical national ranges look like this:

These are typical ranges — your local price can land outside them. A few practical notes worth knowing:

• You don't need a Costco membership to use Costco Pharmacy. Costco's customer service confirms anyone can buy prescriptions there, online or in-warehouse. Member-only Costco pharmacy savings programs may still require a membership.
• GoodRx, SingleCare, and RxSaver coupons can reduce the price, but the discount on Mounjaro is usually modest compared to what those tools achieve on generics. Always check the live coupon price before you transfer the prescription.
• The savings card and GoodRx are mutually exclusive on the same fill. You can't stack them. If you're commercially insured and qualify for the $25 path, that's almost always cheaper than any third-party coupon.

What it costs over a year

A 28-day supply means 13 fills per year, not 12. Quick math:

• At Lilly's $1,112.16 list price: about $14,458/year
• At a Costco $995 cash price: about $12,935/year
• At a specialty pharmacy at $1,300+: about $16,900/year

Lilly raised the WAC from $1,069.08 to $1,112.16 on January 1, 2026 — about a 4% bump. If you're reading an article that quotes “$1,069” or “$1,080” with a 2025 publish date, mentally adjust upward.

Why do some people pay $25, others $499, and the rest $1,100+?

The short answer: those three prices apply to three different people, not three options for the same person. Eli Lilly's Mounjaro Savings Card has separate rules for different insurance situations, and your coverage type decides almost everything. Your uninsured neighbor cannot get the $25 price your coworker pays — even with an identical prescription.

This is the single most important thing to understand before you do anything else.

The $25 price — only for commercially insured patients with coverage

To pay $25 with the Mounjaro Savings Card, all five of these have to be true:

• U.S. or Puerto Rico resident
• Age 18 or older
• You have commercial (private) prescription drug insurance — through an employer, marketplace plan, or private purchase
• Your plan covers Mounjaro for an FDA-approved use (currently, type 2 diabetes in adults and children 10 and older)
• You have a valid Mounjaro prescription

If all five are true, the savings card brings your cost down to $25 for up to a 3-month supply. Maximum annual savings under this tier are up to $1,950 per calendar year. The current card expires 12/31/2026 (Lilly typically renews these year over year, but verify before relying on it for 2027).

The card is excluded for anyone on Medicare, Medicaid, TRICARE, VA coverage, or any other government-funded plan. That exclusion comes from federal anti-kickback law — it isn't a Lilly choice; it applies to every brand-name drug coupon in the U.S.

The $499 price — commercially insured but plan won't cover it

This is the path most people miss. If you have commercial insurance but your plan doesn't cover Mounjaro, Lilly offers a separate savings card tier where you may pay as low as $499 for a 1-month fill. Maximum annual savings under this tier are up to $8,411 per calendar year.

It's still expensive, but it's roughly half the retail cash price and worth checking if you have private insurance and got a non-covered denial. Verify Lilly's current terms at mounjaro.lilly.com/savings-resources before filling, since terms and caps update.

The $1,000–$1,300 price — everyone else

If you're truly uninsured, on Medicare or Medicaid, or your commercial plan denied Mounjaro and you don't fit the $499 path, you're paying retail cash. That's the $995–$1,300 range above. This is the bucket most people who searched “Mounjaro cost without insurance” actually fall into. The $25 advertising you've been seeing isn't a lie — it's just not for you.

Three buckets, three prices

Can you use the Mounjaro Savings Card without insurance?

No. The Mounjaro Savings Card cannot be used without insurance. It requires commercial (private) drug insurance and a prescription for an FDA-approved use of Mounjaro — currently type 2 diabetes in adults and children age 10 and older. Anyone uninsured, on Medicare, Medicaid, TRICARE, VA, or any other government-funded program is excluded by Lilly's terms.

We're going to be direct about this because the gap between what people see in ads and what they actually qualify for is causing real financial harm.

What the $25 ads actually mean

When you see “Mounjaro for $25/month” in an Instagram or TikTok ad, three crucial conditions are usually buried or missing:

1. You have commercial drug insurance
2. That insurance covers Mounjaro
3. The prescription is for an FDA-approved use

Miss any of those three and the $25 price doesn't exist for you. There is no workaround. You can't sign up for a fake insurance plan, you can't switch states, and there's no off-label coupon channel — federal law and Lilly's contract specifically prohibit it.

Why your first fill might have been $25 even though you're uninsured

• First-fill courtesy benefit. Some pharmacies absorb part of the first fill as a loss leader on new patients. This stops at the second fill.
• Old promotional pricing. Some telehealth platforms and compounding pharmacies ran intro pricing in 2024 that's no longer available.
• Pharmacy error. Occasionally a coupon was applied that shouldn't have been. Refills correct it.

What to do if you have commercial insurance and aren't sure if Mounjaro is covered

Two free moves before you guess:

1. Call the number on your insurance card. Ask: “Is Mounjaro on my formulary, and does my plan require prior authorization for it?” That's the question. Most reps can answer in five minutes.
2. Ask your prescriber's office to run a benefits verification. Most diabetes and weight-management practices do this routinely.

If your insurance covers Mounjaro at the savings-card eligible level, your monthly cost drops from $1,000+ to $25. That's a $12,000-a-year decision. Worth the phone call.

The cheapest legitimate path most pages don't tell you about

If your prescription for Mounjaro is for off-label weight loss — meaning you don't have type 2 diabetes — a clinician may be able to switch you to Zepbound and get you single-dose vials directly through LillyDirect or through Ro's LillyDirect integration at $299 to $449 per month, depending on dose. Same active ingredient (tirzepatide), same manufacturer (Eli Lilly), and the brand that's actually FDA-approved for chronic weight management.

This isn't a workaround. It isn't compounded. It isn't a generic. Mounjaro and Zepbound are separate FDA-approved Eli Lilly products that contain the same active ingredient at identical doses, with different FDA labels and different access pathways.

Why Zepbound is so much cheaper

The difference is the FDA-approved indication on the label:

• Mounjaro — FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes
• Zepbound — FDA-approved for chronic weight management in qualifying adults with obesity (or overweight + a weight-related condition), and for moderate-to-severe obstructive sleep apnea in adults with obesity

Zepbound's actual self-pay pricing (read this carefully)

Lilly's Zepbound Self Pay Journey Program prices, available exclusively through LillyDirect (or partners like Ro that integrate with LillyDirect):

• $299/month for the 2.5 mg starter dose
• $399/month for the 5 mg dose
• $449/month for 7.5 mg, 10 mg, 12.5 mg, and 15 mg — but only if you complete each refill within 45 days of your last delivery

When the switch makes sense

Switching from Mounjaro to Zepbound is worth discussing with a clinician if all three of these apply:

1. Your Mounjaro prescription is for off-label weight loss, not for type 2 diabetes
2. You meet Zepbound's FDA-approved criteria — typically a BMI of 30 or higher, or BMI 27+ with a weight-related condition (high blood pressure, high cholesterol, sleep apnea, etc.)
3. You're paying cash, or your insurance won't cover Mounjaro for off-label use

When the switch does NOT make sense

• Don't switch if you have type 2 diabetes and your insurance covers Mounjaro at $25. You're already on the cheapest legitimate path. Zepbound at $299–$449 would be more than 10x what you're paying.
• Don't switch if you can't or won't draw a dose from a vial. LillyDirect's lowest pricing is on single-dose vials, which require a syringe and one extra prep step. Lilly's Zepbound multi-dose KwikPen is also available at the same self-pay tiers ($299/$399/$449 with the 45-day rule), but availability rolls out gradually — verify before committing.
• Don't switch if your prescriber has a clinical reason to keep you on Mounjaro specifically. That's their call. Ask, but don't push.

Exactly what to ask your prescriber

Most patients who'd benefit from this switch never ask, because they don't know it's possible. Take this four-line script to your next appointment, your patient portal, or your telehealth provider:

“I'm currently prescribed Mounjaro for weight management. Since this is an off-label use, would Zepbound be more appropriate? It contains the same active ingredient and is FDA-approved for chronic weight management. The LillyDirect single-dose vials are $299–$449 per month, compared to over $1,000 for Mounjaro retail.”

What it actually costs at CVS, Walgreens, Walmart, and Costco

Mounjaro pharmacy prices vary by chain, ZIP code, dose-specific NDC code, inventory, and coupon vendor. Costco and Sam's Club consistently come in lowest at around $995–$1,100/month. CVS and Walgreens cluster between $1,000 and $1,200. Specialty and independent pharmacies usually run highest, sometimes hitting $1,500. The pharmacy you choose can change your annual cost by $2,000 or more for the exact same prescription. This is worth five minutes.

How to find the cheapest pharmacy in your area

1. Run your prescription details through GoodRx. Enter Mounjaro, your dose (2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg), and your ZIP code. GoodRx shows the coupon-adjusted price at every pharmacy near you.
2. Cross-check with SingleCare and RxSaver. Different vendors negotiate different rates with each chain. SingleCare often beats GoodRx at one chain and not another.
3. Call Costco directly if Costco doesn't appear in the coupon results. Costco's pharmacy cash prices sometimes beat coupon-adjusted prices at chains, and they'll quote you over the phone in 60 seconds.
4. Confirm before transferring. Coupon prices change. Stock changes. Ask the pharmacy: “If I have a Mounjaro prescription transferred here today, what's the cash price for [dose] mg?”

Coupon stacking — does it work?

The Mounjaro Savings Card and GoodRx are mutually exclusive on the same fill. You can't use both. If you have commercial insurance and qualify for the $25 savings card path, that's almost always cheaper than any coupon.

GoodRx, SingleCare, and similar tools are most useful for Medicare patients (who can't use the savings card) and for cash-pay patients without other options.

Patients regularly find that the same Mounjaro prescription, same dose, same NDC, varies by $200 or more between two pharmacies a few miles apart in the same city. The 30-second move — checking GoodRx in your ZIP, then calling the lowest result — is one of the most consistently undervalued cost-saving steps. Make the call before you fill.

Pharmacy shock — what to do when your refill jumps to $1,000+

If your first Mounjaro fill was $25 (or any low number) and your refill suddenly costs $1,000 or more, don't pay it yet and don't run to an unverified online seller. The most common causes are insurance denials, prior authorization expiring, savings-card routing errors, or coverage rules changing — and each one has a fix. Run the seven-step checklist before you panic-buy.

The 7-step pharmacy shock checklist

Does Medicare, Medicaid, VA, or TRICARE cover Mounjaro?

Government insurance plans cannot use the Mounjaro Savings Card — federal law excludes Medicare, Medicaid, TRICARE, VA, and similar programs from manufacturer copay programs. Coverage of Mounjaro itself depends on your plan. Most Medicare Part D plans cover Mounjaro for type 2 diabetes with prior authorization. According to Lilly, about 8 in 10 Medicare Part D patients pay $0–$50 for a 28-day supply, and Medicaid copays average roughly $5–$11. Coverage for off-label weight loss is rare.

Medicare Part D — what's covered now

For type 2 diabetes patients, most Medicare Part D plans cover Mounjaro. Typical out-of-pocket cost depends on your plan's formulary tier (usually Tier 3), whether prior authorization is required (almost always), and where you are in your annual deductible cycle.

A useful 2026 detail: Medicare Part D enrollees won't pay more than $2,100 in out-of-pocket prescription costs in 2026, thanks to the Inflation Reduction Act cap. Even if your plan tier is high, your annual ceiling is hard-capped.

Medicare and weight loss — the new GLP-1 Bridge program

Medicare has historically excluded weight-loss medications from Part D coverage. That's changing in 2026 under the Medicare GLP-1 Bridge — a CMS demonstration program. Here's exactly what's happening:

• Program runs July 1, 2026 through December 31, 2027
• Eligible Medicare Part D beneficiaries pay $50/month for covered weight-loss GLP-1 medications
• Eligible products: all formulations of Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound only — Zepbound single-dose vials and pens are not covered under the Bridge
• Mounjaro is not on the Bridge eligible products list. Mounjaro is FDA-approved for type 2 diabetes, not weight loss; the Bridge is specifically a weight-loss demonstration.

Eligibility criteria for the Bridge:

• Enrolled in a standalone Part D Plan (PDP) or Medicare Advantage with drug coverage
• Prior authorization meeting one of these:
  • BMI ≥ 35
  • BMI ≥ 30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above
  • BMI ≥ 27 with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease

See our full guide: Does Medicare cover Mounjaro for weight loss? →

Medicaid — varies by state

State Medicaid programs cover Mounjaro for type 2 diabetes in varying configurations, with prior authorization typically required. Coverage for off-label weight loss is rare. State Medicaid agencies can join the BALANCE Model for GLP-1 obesity coverage starting May 2026 through January 2027. Verify your state's preferred drug list with your case manager.

TRICARE

TRICARE covers Mounjaro for type 2 diabetes when clinical criteria, prior authorization, and medical necessity requirements are met. The Mounjaro Savings Card is not usable by TRICARE beneficiaries.

VA

Tirzepatide injection is not on the VA national formulary as of current records. VA patients seeking Mounjaro typically need a non-formulary drug request and prior approval through VA pharmacy channels. Verify directly with your VA pharmacy benefits manager.

What to do if you're on government insurance

1. Confirm your plan's coverage rules for Mounjaro. Call the number on your card; ask specifically about your indication.
2. Get prior authorization started immediately if needed. Your prescriber's office has the paperwork.
3. If you're prescribed Mounjaro for off-label weight loss, talk to your prescriber about Zepbound or Wegovy — both are on-label for weight management. Once the Medicare GLP-1 Bridge activates July 1, 2026, eligible beneficiaries pay $50/month for these products.
4. If cost is unmanageable, ask your prescriber about Lilly's patient assistance options — verify current Mounjaro inclusion at lillycares.com.

Mounjaro vs. Zepbound — different brands, same molecule, very different cash prices

Mounjaro and Zepbound are separate FDA-approved Eli Lilly products that contain the same active ingredient — tirzepatide — at identical doses (2.5 mg through 15 mg). Their FDA labels and approved uses are different: Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for chronic weight management and obstructive sleep apnea in adults with obesity. For cash-pay patients, the difference between them is several hundred dollars a month because Lilly built a direct-to-consumer self-pay program for Zepbound that doesn't yet exist for Mounjaro.

Side by side at a glance

Average weight loss in clinical trials

In SURMOUNT-1, the pivotal Zepbound (tirzepatide) chronic-weight-management trial, adults at the highest dose lost an average of about 20% of body weight at 72 weeks. That clinical context is relevant to anyone evaluating which product fits their goal.

How tirzepatide costs compare to other GLP-1 medications

Quick category snapshot at May 2026 cash pricing:

For pure cash-pay weight loss in 2026, Zepbound vials (or KwikPen) and the Wegovy oral pill are the two most affordable FDA-approved paths. Foundayo is the new oral GLP-1 entrant — note that orforglipron is a different molecule from tirzepatide, not “tirzepatide-class.” See our Mounjaro vs. Ozempic comparison →

Is there a generic Mounjaro or cheaper compounded tirzepatide?

There is no FDA-approved generic for Mounjaro. Tirzepatide is under patent protection through at least the mid-2030s. Compounded tirzepatide is not FDA-approved. The FDA officially declared the tirzepatide injection shortage resolved on December 19, 2024, and the enforcement-discretion windows that allowed broader compounding ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. Large-scale compounding of tirzepatide as essentially a copy of Mounjaro or Zepbound has been restricted since.

What “compounded tirzepatide” actually is

Compounding pharmacies make custom medications for patients who can't take a commercially available drug for documented reasons. During the 2023–2024 tirzepatide shortage, FDA temporarily allowed broader compounding because Mounjaro and Zepbound were not consistently available. That changed in late 2024 / early 2025. With the shortage resolved, compounding pharmacies can no longer mass-produce essentially a copy of Mounjaro or Zepbound. Narrow exceptions exist for documented patient-specific medical needs — but these are not “we make it cheaper” loopholes.

Why we're not recommending compounded tirzepatide on this page

1. Mounjaro is an FDA-approved brand. Pointing readers toward an unapproved alternative crosses a line we won't cross.
2. The FDA is actively warning consumers. The FDA has issued direct guidance that companies cannot describe non-FDA-approved compounded products as generic versions, the same as FDA-approved drugs, or clinically proven to produce the same results.
3. The cheapest legitimate FDA-approved alternative already exists. Zepbound vials at $299–$449 through LillyDirect are the actual answer. Same active ingredient, same manufacturer, FDA-approved, made under FDA-regulated quality controls.
4. Some “compounded tirzepatide” sellers aren't compounding pharmacies at all. The FDA has issued direct warnings that some unapproved GLP-1 products may be counterfeit, contain incorrect amounts of active ingredient, too little, too much, or none. We won't point you to these.

Red flags on online sellers

Walk away from any seller that:

• Doesn't require a prescription
• Markets it as “research only” or “research peptide”
• Won't identify the dispensing pharmacy
• Claims to offer “Mounjaro” specifically (Mounjaro is a Lilly brand; nobody else legally sells it under that name)
• Operates internationally without U.S. licensing
• Offers prices that seem too cheap (e.g., $99/month for “tirzepatide”)

See also: Compounded GLP-1 alternatives: current legal and safety status →

How to get a Mounjaro prescription online without insurance

You can get a legitimate Mounjaro prescription online through licensed telehealth providers, but the prescription itself doesn't make Mounjaro cheap — medication cost is separate from visit/membership fees. The two strongest options for online Mounjaro access are Sesame Care (which has Mounjaro available, supports prior authorization, and lets you choose your provider) and your existing primary care or endocrinology practice.

Online provider quick reality check

Sesame Care — the strongest telehealth option for Mounjaro specifically

If you want a prescription for Mounjaro through telehealth, Sesame Care is the most flexible legitimate option:

• Mounjaro is on Sesame's formulary for type 2 diabetes patients, alongside Zepbound, Wegovy, Ozempic, Foundayo, and other GLP-1 medications
• Provider choice — you pick your own clinician from profiles, reviews, and credentials. Most other telehealth platforms assign you one.
• Prior authorization assistance — Sesame providers can submit PA paperwork to your insurance, which often turns a $1,000+ cash price into a $25 covered price
• Costco partnership for Wegovy and Ozempic injections at $349/month (50% off retail) for Costco members; Wegovy oral pill starting as low as $149/month for eligible doses
• Subscription model: Success by Sesame is $59/month with an annual plan, or $99/month otherwise. Medication cost is separate.

The honest tradeoff: Sesame doesn't manufacture Mounjaro at a discounted cash price. The $1,000+ pharmacy price still applies if you're paying cash without coverage. Sesame's value is in (a) providing a legitimate prescription, (b) helping you get insurance coverage, and (c) routing you to the cheapest covered option for your situation, which may or may not be Mounjaro.

Ro — primary option only if you'll consider switching to Zepbound

Ro doesn't currently carry Mounjaro. Their FDA-approved weight management lineup is Zepbound (pen and KwikPen), Wegovy (pill and pen), and Foundayo. If your Mounjaro prescription is for off-label weight loss, Ro is the most direct path to switching to Zepbound at LillyDirect cash prices — they integrate directly with LillyDirect for Zepbound vial pricing. If you want to specifically stay on Mounjaro, Ro isn't your provider.

What to ask any online provider before booking

• Is a licensed clinician reviewing my case (not just an algorithm)?
• Is the prescription written by a clinician licensed in my state?
• What's the total monthly cost — visit fee + medication?
• Will you submit prior authorization to my insurance?
• Which dispensing pharmacy will fulfill the prescription?
• What happens if my insurance denies coverage?

If a provider can't answer all six clearly, look elsewhere.

What's changing in 2026

The Mounjaro pricing landscape shifted significantly between November 2025 and May 2026. Eli Lilly raised the Mounjaro list price to $1,112.16 on January 1, 2026 (about a 4% increase). The November 2025 White House Most Favored Nation deal committed Lilly to lower Medicare/Medicaid prices and add new direct-to-consumer pathways. The Medicare GLP-1 Bridge launches July 1, 2026 with $50/month copays for eligible obesity patients. TrumpRx is already live (trumprx.gov) with discounted GLP-1 pricing. And Foundayo (orforglipron), Lilly's first oral daily GLP-1, was FDA-approved on April 1, 2026.

November 2025 Most Favored Nation deal

On November 6, 2025, the White House announced agreements with Eli Lilly and Novo Nordisk applying Most Favored Nation pricing to GLP-1 medications. Headlines for Mounjaro patients:

• Medicare/Medicaid program price for Mounjaro: $245/month, decreasing over a 24-month transition
• Medicare patient copay capped at $50/month for eligible beneficiaries where Medicare covers Mounjaro for diabetes
• Mounjaro announced to be added to LillyDirect at 50–60% off list price for self-pay patients — implementation is rolling out, verify live availability at lilly.com/lillydirect before relying on this path

TrumpRx — already live

TrumpRx.gov launched and is live with discounted GLP-1 pricing. As of current verification, the public price cards show:

• Wegovy Pill: starting at $149/month
• Wegovy Pen: starting at $199/month
• Ozempic: starting at $199/month
• Zepbound Vial and KwikPen: starting at $299/month (LillyDirect manages fulfillment)

Mounjaro is not currently visible on TrumpRx public price cards. Check trumprx.gov directly before relying on Mounjaro pricing there.

Foundayo (orforglipron) — FDA-approved April 1, 2026

Lilly's first oral daily GLP-1 — orforglipron, brand name Foundayo — was FDA-approved for chronic weight management on April 1, 2026. Important: orforglipron is a different molecule from tirzepatide. Self-pay pricing through LillyDirect:

• $149/month for the 0.8 mg starter dose
• $199/month for 2.5 mg
• $299/month for 5.5 mg and 9 mg
• $349/month for 14.5 mg and 17.2 mg (with a $299 high-dose offer if refilled within 45 days of last delivery)

Foundayo is also one of the eligible products in the Medicare GLP-1 Bridge.

What this means for you right now

What we actually verified for this guide

We verified every commercial price and eligibility rule in this guide against primary sources within the past 90 days.

What we verified

What we did not verify

• Your specific insurance coverage. Coverage rules vary by plan, employer, and state. Verify directly with your insurer.
• Your specific Mounjaro Savings Card eligibility. Lilly's eligibility check is the only source of truth.
• ZIP-code-specific pharmacy prices. Costco in one city may be $989; another may be different. Spot-check before transferring a prescription.
• Mounjaro live availability on LillyDirect or TrumpRx. Both were announced as expanding to include Mounjaro; verify at the official platforms before relying on those paths.
• Patient assistance program coverage of Mounjaro. Lilly's available-medications list updates over time; verify current Mounjaro inclusion at lillycares.com.

How we decide what to recommend

1. Evidence of fit for the reader's specific situation. A T2D patient with commercial coverage shouldn't be routed to Zepbound. An off-label weight loss patient shouldn't be told the $25 card applies. We segment the answer.
2. Verified primary source for every commercial claim. No price quoted on this page exists without a primary source within the last 90 days.
3. Editorial conclusions clearly framed as conclusions. Our recommendations are based on verified facts but are editorial synthesis, not medical advice. Decisions about prescriptions belong to you and your prescriber.

We accept commissions from some provider links on this page. We do not accept compensation in exchange for changing prices, eligibility rules, FDA status, or any factual claim.

Quick answers (FAQ)

What to do next

If you've read this far, you have one of four situations. Here's the clearest next step for each.

Related guides

• Mounjaro vs. Ozempic — cost, results, and which fits you
• How to switch from Mounjaro to Zepbound
• Zepbound cost without insurance
• Does Medicare cover Mounjaro for weight loss?
• Compounded tirzepatide — current legal and safety status
• Best FDA-approved GLP-1 telehealth providers

Sources

This guide was researched against primary sources. Prices and program terms verified as of May 7, 2026.

• Eli Lilly. Mounjaro Cost Information — pricinginfo.lilly.com/mounjaro
• Eli Lilly. Mounjaro Savings & Resources — mounjaro.lilly.com/savings-resources
• Eli Lilly. Mounjaro Savings Card Terms and Conditions — mounjaro.lilly.com/fragments/terms-and-conditions-column
• Eli Lilly. Zepbound Cost Information and Self Pay Journey Program — pricinginfo.lilly.com/zepbound and zepbound.lilly.com
• Eli Lilly. Foundayo Self-Pay Pricing and Terms — lilly.com/lillydirect/medicines/foundayo
• Eli Lilly. LillyDirect platform and currently available medicines — lilly.com/lillydirect/medicines
• Eli Lilly. Lilly and U.S. Government Agreement Press Release, November 6, 2025
• Eli Lilly. Mounjaro Prescribing Information — pi.lilly.com/us/mounjaro-uspi.pdf
• DailyMed. Mounjaro and Zepbound prescribing information
• FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products
• FDA. Intent to Take Action Against Non-FDA-Approved GLP-1 Drugs
• CMS. Medicare GLP-1 Bridge program guidance — cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
• CMS. BALANCE Model — cms.gov/priorities/innovation/innovation-models/balance
• The White House. Fact Sheet: Most-Favored-Nation Pricing announcements, November 6, 2025
• Costco Customer Service. Pharmacy non-member access
• Ro. Zepbound program pricing — ro.co/weight-loss/zepbound
• Sesame Care. Mounjaro and tirzepatide pages — sesamecare.com/medication/mounjaro
• TRICARE. GLP-1 coverage FAQ — tricare.mil
• VA Formulary Advisor. Tirzepatide injection non-formulary status
• TrumpRx. Live price cards — trumprx.gov
• GoodRx. Mounjaro pricing database — goodrx.com/mounjaro
• KFF. Medicaid Coverage of and Spending on GLP-1s